RU2745557C3 - Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование - Google Patents

Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование

Info

Publication number
RU2745557C3
RU2745557C3 RU2018139379A RU2018139379A RU2745557C3 RU 2745557 C3 RU2745557 C3 RU 2745557C3 RU 2018139379 A RU2018139379 A RU 2018139379A RU 2018139379 A RU2018139379 A RU 2018139379A RU 2745557 C3 RU2745557 C3 RU 2745557C3
Authority
RU
Russia
Prior art keywords
alpha
sialylation
fsh
stimulating hormone
recombinant follicle
Prior art date
Application number
RU2018139379A
Other languages
English (en)
Other versions
RU2745557C1 (ru
Original Assignee
Ферринг Интернэшнл Сентер СА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2745557(C3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ферринг Интернэшнл Сентер СА filed Critical Ферринг Интернэшнл Сентер СА
Application granted granted Critical
Publication of RU2745557C1 publication Critical patent/RU2745557C1/ru
Publication of RU2745557C3 publication Critical patent/RU2745557C3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (1)

  1. Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий α2,3- и α2,6-сиалирование, где от 11,5 до 15,76% общего сиалирования рекомбинантного ФСГ представляет собой α2,6-сиалирование, обеспеченное активностью эндогенной сиалилтрансферазы, экспрессированный в клеточной линии Реr.С6, которая модифицирована с использованием α2,3-сиалилтрансферазы.
RU2018139379A 2008-04-16 2018-11-08 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование RU2745557C3 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014141994A Division RU2682270C2 (ru) 2008-04-16 2009-04-16 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021105626A Division RU2021105626A (ru) 2021-03-04 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование

Publications (2)

Publication Number Publication Date
RU2745557C1 RU2745557C1 (ru) 2021-03-29
RU2745557C3 true RU2745557C3 (ru) 2021-12-10

Family

ID=39717519

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2014141994A RU2682270C2 (ru) 2008-04-16 2009-04-16 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование
RU2010141908/10A RU2537268C2 (ru) 2008-04-16 2009-04-16 Рекомбинантный фолликулостимулирующий гормон (фсг), включающий альфа-2, 3- и альфа-2, 6-сиалирование
RU2018139379A RU2745557C3 (ru) 2008-04-16 2018-11-08 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2014141994A RU2682270C2 (ru) 2008-04-16 2009-04-16 Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование
RU2010141908/10A RU2537268C2 (ru) 2008-04-16 2009-04-16 Рекомбинантный фолликулостимулирующий гормон (фсг), включающий альфа-2, 3- и альфа-2, 6-сиалирование

Country Status (29)

Country Link
US (5) US8951967B2 (ru)
EP (7) EP3098234A1 (ru)
JP (7) JP2011519359A (ru)
KR (5) KR20160056960A (ru)
CN (3) CN105906703A (ru)
AR (1) AR071479A1 (ru)
AU (5) AU2009237479B2 (ru)
BR (1) BRPI0910461B8 (ru)
CA (1) CA2725257A1 (ru)
CY (1) CY1115413T1 (ru)
DK (4) DK2808340T3 (ru)
ES (3) ES2468318T3 (ru)
FR (1) FR17C1020I2 (ru)
HK (2) HK1146284A1 (ru)
HR (3) HRP20140535T1 (ru)
HU (5) HUE033830T2 (ru)
IL (2) IL208538A (ru)
LT (4) LT2808340T (ru)
MX (3) MX2010011343A (ru)
NO (2) NO2017025I1 (ru)
NZ (1) NZ588381A (ru)
PL (4) PL2268666T3 (ru)
PT (4) PT3144318T (ru)
RU (3) RU2682270C2 (ru)
SA (1) SA109300228B1 (ru)
SI (4) SI2808340T1 (ru)
TW (1) TWI488640B (ru)
WO (1) WO2009127826A1 (ru)
ZA (1) ZA201007373B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2848687B1 (en) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Novel expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
JP7079094B2 (ja) 2015-04-17 2022-06-01 フェリング ベスローテン フェンノートシャップ 不妊症の処置のための組成物
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
ES2904787T3 (es) 2017-09-01 2022-04-06 Ferring Bv Composición para la estimulación ovárica controlada
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
KR20210079276A (ko) 2018-10-17 2021-06-29 훼링 비.브이. 제어된 난소 자극을 위한 조성물 및 방법
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
WO1998031826A1 (en) 1997-01-16 1998-07-23 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
ATE332705T1 (de) 1999-05-07 2006-08-15 Applied Research Systems Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
RS32804A (en) * 2001-10-22 2007-02-05 Applied Research Systems Ars Holding N.V., Gonadotrophins for folliculogenesis
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ES2350298T3 (es) 2004-02-04 2011-01-20 Centre National De La Recherche Scientifique Procedimiento para el cribado de anticuerpos específicos de glicoforma.
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
WO2012042381A1 (en) 2010-09-29 2012-04-05 Ferring B.V. Composition for controlled ovarian stimulation
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
BR112016023668A2 (pt) 2014-04-18 2017-10-17 Glycotope Gmbh hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Also Published As

Publication number Publication date
BRPI0910461B1 (pt) 2021-02-23
TW200948378A (en) 2009-12-01
JP6762916B2 (ja) 2020-09-30
LTPA2017018I1 (lt) 2017-06-26
LT3045471T (lt) 2017-07-10
CN102066414A (zh) 2011-05-18
IL230571A (en) 2015-11-30
RU2014141994A3 (ru) 2018-05-28
DK2808340T3 (en) 2016-12-05
EP2268666A1 (en) 2011-01-05
HRP20140535T1 (hr) 2014-07-18
US9771407B2 (en) 2017-09-26
JP2022031652A (ja) 2022-02-22
DK3144318T3 (da) 2020-12-07
US10995128B2 (en) 2021-05-04
PT3144318T (pt) 2020-11-04
US20180079794A1 (en) 2018-03-22
WO2009127826A1 (en) 2009-10-22
KR20180095140A (ko) 2018-08-24
PT3045471T (pt) 2017-06-14
EP3045471B1 (en) 2017-03-29
KR101622944B1 (ko) 2016-05-23
JP2011519359A (ja) 2011-07-07
EP4015527A1 (en) 2022-06-22
AU2014203277C1 (en) 2017-07-27
AU2017204258A1 (en) 2017-07-20
JP2015120696A (ja) 2015-07-02
RU2682270C2 (ru) 2019-03-18
ES2468318T3 (es) 2014-06-16
MX355457B (es) 2018-04-19
HRP20161520T1 (hr) 2016-12-30
HK1199039A1 (en) 2015-06-19
JP2020040956A (ja) 2020-03-19
RU2010141908A (ru) 2012-05-27
JP2024038000A (ja) 2024-03-19
US20110105398A1 (en) 2011-05-05
CN105906702A (zh) 2016-08-31
PL3144318T3 (pl) 2021-02-08
AU2017204259A1 (en) 2017-07-20
US20210332099A1 (en) 2021-10-28
EP2268666B1 (en) 2014-03-12
AU2014203277A1 (en) 2014-07-24
KR102108377B1 (ko) 2020-05-08
PL3045471T3 (pl) 2017-10-31
EP2722339A1 (en) 2014-04-23
US20150065695A1 (en) 2015-03-05
BRPI0910461A2 (pt) 2018-03-27
ZA201007373B (en) 2011-06-29
HUE030652T2 (en) 2017-05-29
AR071479A1 (es) 2010-06-23
DK3045471T3 (en) 2017-06-26
SI2808340T1 (sl) 2016-12-30
US11952407B2 (en) 2024-04-09
RU2745557C1 (ru) 2021-03-29
FR17C1020I1 (ru) 2020-04-10
HUE033830T2 (en) 2018-01-29
RU2014141994A (ru) 2016-05-10
AU2009237479B2 (en) 2014-05-15
JP2018021037A (ja) 2018-02-08
EP3098234A1 (en) 2016-11-30
NO2017050I1 (no) 2017-09-28
JP7316905B2 (ja) 2023-07-28
CN105906703A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
ES2610277T3 (es) 2017-04-26
HUS1700036I1 (hu) 2017-10-30
SI3144318T1 (sl) 2020-12-31
JP6486310B2 (ja) 2019-03-20
DK2268666T3 (da) 2014-05-12
KR20160056960A (ko) 2016-05-20
EP3144318A1 (en) 2017-03-22
PL2268666T3 (pl) 2014-08-29
KR20110005863A (ko) 2011-01-19
EP2808340A1 (en) 2014-12-03
SA109300228B1 (ar) 2014-04-08
RU2537268C2 (ru) 2014-12-27
LT2808340T (lt) 2016-11-10
NZ588381A (en) 2012-05-25
US20160347811A1 (en) 2016-12-01
HUE030652T4 (en) 2017-09-28
PL2808340T3 (pl) 2017-02-28
AU2017225020A1 (en) 2017-09-28
KR20170110741A (ko) 2017-10-11
PT2268666E (pt) 2014-06-25
AU2017204258B2 (en) 2017-08-17
MX348622B (es) 2017-06-22
IL208538A (en) 2014-03-31
IL208538A0 (en) 2010-12-30
HK1146284A1 (en) 2011-05-20
US8951967B2 (en) 2015-02-10
HUS1700025I1 (hu) 2017-06-28
LTPA2017029I1 (lt) 2017-10-10
AU2017225020B2 (en) 2019-11-14
ES2629392T3 (es) 2017-08-09
NO2017025I1 (no) 2017-06-06
US9546204B2 (en) 2017-01-17
CY1115413T1 (el) 2017-01-04
BRPI0910461B8 (pt) 2021-05-25
PT2808340T (pt) 2016-11-21
AU2009237479A1 (en) 2009-10-22
EP3144318B1 (en) 2020-09-23
TWI488640B (zh) 2015-06-21
AU2017204259B2 (en) 2017-08-17
CA2725257A1 (en) 2009-10-22
AU2014203277B2 (en) 2017-04-06
BRPI0910461A8 (pt) 2018-10-16
MX2010011343A (es) 2011-01-20
HRP20170958T1 (hr) 2017-09-22
KR20190092608A (ko) 2019-08-07
SI3045471T1 (sl) 2017-07-31
HUS1700024I1 (hu) 2017-06-28
FR17C1020I2 (fr) 2020-04-10
EP2808340B1 (en) 2016-08-17
JP2017060476A (ja) 2017-03-30
SI2268666T1 (sl) 2014-07-31

Similar Documents

Publication Publication Date Title
RU2745557C3 (ru) Рекомбинантный фолликулостимулирующий гормон (ФСГ), включающий альфа-2,3- и альфа-2,6-сиалирование
AR125991A2 (es) Preparación farmacéutica
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
JP2011527560A5 (ru)
DK2375907T3 (da) Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
MX2012011840A (es) Estructuras multimericas especificas para ligado inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trial).
JP2010500717A5 (ru)
RS54905B1 (sr) Poboljšani rekombinantni humani folikulo-stimulišući hormon
WO2011139702A3 (en) Modified nucleosides and oligomeric compounds prepared therefrom
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
MX2012013375A (es) Peptido c pegilado.
MX343360B (es) Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
BR112012001105A2 (pt) produção de ácido acético por meio de carbonilação com uma reação e vaporização instantânea melhoradas
BR112015024609A2 (pt) proteína tendo atividade de xilose isomerase e utilização da mesma
WO2013093760A3 (en) Compositions, methods, and kits for preparing sialylated recombinant proteins
CA2891921C (en) Peroxide-stable oral care compositions
PH12015501623A1 (en) Glyco-modified atrial natriuretic peptide
EA201171449A1 (ru) Обратная генетика с использованием неэндогенных промоторов pol 1
JP2011528382A5 (ru)
JP2011518813A5 (ru)
WO2011156807A3 (en) Titania-alumina-tungsta extrudate and its use
NL2002510A1 (nl) Extrapolating ICA knowledge from one epoch to another for improved fetal ECG separation.
WO2012115903A3 (en) Yeast strain for the production of proteins with modified o-glycosylation

Legal Events

Date Code Title Description
ND4A Extension of patent duration

Effective date: 20211210

TK4A Correction to the publication in the bulletin (patent)

Free format text: CORRECTION TO CHAPTER -ND4A- IN JOURNAL 34-2021

ND4A Extension of patent duration

Effective date: 20220209